IGF2BP2 and lung adenocarcinoma: Wu et al [17] used univariate and LASSO Cox regression analysis to develop a m6A regulator prognostic signature composed of HNRNPC, METTL3, HNRNA2B1, IGF2BP1, and IGF2BP2 for lung adenocarcinoma based on RNA-seq, clinicopathological, and single nucleotide variation data retrieved from the TCGA database.[17] Also, Yang et al[18] found that HNRNPC and KIAA1429 can be regarded as potential prognostic markers in papillary renal cell carcinoma by using the similar method.